SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-21-050686
Filing Date
2021-09-30
Accepted
2021-09-30 06:12:25
Documents
4
Group Members
EDWARD TERINOJAMES C. ROUMELLMATTHEW M. LOARROUMELL OPPORTUNISTIC VALUE FUNDSUSANNE L. MELINE

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 15 TO SCHEDULE 13D ea148169-13da15roumell_enzo.htm SC 13D/A 168804
2 TERMINATION OF JOINT FILING AND SOLICITATION AGREEMENT, DATED SEPTEMBER 29, 2021 ea148169ex99-1_enzobiochem.htm EX-99.1 9630
3 JOINT FILING AND SOLICITATION AGREEMENT BY AND AMONG THE REPORTING PERSONS, DATE ea148169ex99-2_enzobiochem.htm EX-99.2 18818
4 FORM OF INDEMNIFICATION LETTER AGREEMENT ea148169ex99-3_enzobiochem.htm EX-99.3 14583
  Complete submission text file 0001213900-21-050686.txt   213515
Mailing Address ENZO BIOCHEM INC 60 EXECUTIVE BLVD FARMINGDALE NY 11735
Business Address 60 EXECUTIVE BLVD FARMINGDALE NY 11735 5167555500
ENZO BIOCHEM INC (Subject) CIK: 0000316253 (see all company filings)

IRS No.: 132866202 | State of Incorp.: NY | Fiscal Year End: 0731
Type: SC 13D/A | Act: 34 | File No.: 005-32878 | Film No.: 211293503
SIC: 8071 Services-Medical Laboratories

Mailing Address 2 WISCONSIN CIR SUITE 700 CHEVY CHASE MD 20815
Business Address 2 WISCONSIN CIR SUITE 700 CHEVY CHASE MD 20815 301-656-8500
Roumell Asset Management, LLC (Filed by) CIK: 0001331693 (see all company filings)

IRS No.: 522145132 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SC 13D/A